Brief: Tango Therapeutics Announces FDA Clearance Of Investigational NDA For TNG462

Tango Therapeutics

25/01/2023 13:04

Jan 25 (Reuters) - Tango Therapeutics Inc  TNGX.O :
    * TANGO THERAPEUTICS ANNOUNCES FDA CLEARANCE OF
INVESTIGATIONAL
NEW DRUG APPLICATION FOR TNG462; PROVIDES ADDITIONAL BUSINESS
UPDATES
    * TANGO THERAPEUTICS INC - TNG462 IND CLEARED;
FIRST-IN-HUMAN
CLINICAL TRIAL INITIATION EXPECTED IN MID-2023
    * TANGO THERAPEUTICS INC - TNG908 WAS GRANTED ORPHAN DRUG
DESIGNATION (ODD) FOR TREATMENT OF MALIGNANT GLIOMA
    * TANGO THERAPEUTICS ANNOUNCES FDA CLEARANCE OF
INVESTIGATIONAL
NEW DRUG APPLICATION FOR TNG462; PROVIDES ADDITIONAL BUSINESS
UPDATES
    * TANGO THERAPEUTICS INC - IND FILING FOR TNG260,
FIRST-IN-CLASS
COREST INHIBITOR, IS ON TRACK FOR FIRST HALF OF 2023
    * TANGO THERAPEUTICS INC - TNG462 IND CLEARED;
FIRST-IN-HUMAN
CLINICAL TRIAL INITIATION EXPECTED IN MID-2023
    * TANGO THERAPEUTICS INC - IND FILING FOR TNG260, A
FIRST-IN-CLASS
COREST INHIBITOR, IS ON TRACK FOR FIRST HALF OF 2023
    * TANGO THERAPEUTICS INC - IND FILING FOR TNG348 IS ON TRACK
FOR
MID-2023
    * TANGO THERAPEUTICS -DOSE ESCALATION UPDATE EXPECTED FROM
PHASE
1/2 CLINICAL TRIAL OF TNG908 IN PATIENTS WITH MTAP-DELETED SOLID
TUMORS IN H1 2023

Source text for Eikon:  ID:nGNX1Fylpd 
Further company coverage:  TNGX.O 
 ((Reuters.Briefs@thomsonreuters.com;))